Updating results

39 results for Apixaban

Sort: Relevance | Date

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published June 2015

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults

Technology appraisal guidance Published January 2012

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

Technology appraisal guidance Published September 2015

Atrial fibrillation: management (CG180)

This guideline covers diagnosing and managing atrial fibrillation in adults. It aims to ensure that people receive the best management to help prevent harmful complications, in particular stroke and bleeding.

Clinical guideline Published June 2014 Last updated August 2014

Venous thromboembolism

Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart

NICE Pathway Published May 2011 Last updated August 2019

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

NICE guideline Published March 2018 Last updated August 2019

Atrial fibrillation

Everything NICE has said on diagnosing and managing atrial fibrillation in an interactive flowchart

NICE Pathway Published June 2014 Last updated May 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

NICE has issued technology appraisal guidance on the use of the 4 DOACs apixaban, dabigatran etexilate, edoxaban and rivaroxaban in...

Key therapeutic topic Published February 2016 Last updated September 2019

Atrial fibrillation. Patient decision aid

anticoagulant, you can choose warfarin or one of the newer drugs such as apixaban, dabigatran or rivaroxaban. Warfarin has been used for...

Published June 2014 Last updated June 2014

Structural heart defects

Everything NICE has said on structural heart defects in an interactive flowchart

NICE Pathway Published November 2013 Last updated June 2019

There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are...

Research recommendation Published June 2015

Block scoping reports

This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

Published July 2019 Last updated July 2019

Atrial fibrillation (QS93)

This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

Quality standard Published July 2015 Last updated February 2018

Static list

NICE technology appraisal guidance static list

Published January 2018 Last updated January 2018

Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction. It aims to promote the health of people who have had an MI by encouraging them to attend a cardiac rehabilitation programme and advising them on a healthy lifestyle. It also includes advice on drug therapy.

Clinical guideline Published November 2013

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Technology appraisal guidance In development

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

Evidence summary Published May 2016

Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting

Diagnostics guidance Published September 2014 Last updated December 2017

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published December 2014

Chronic kidney disease: managing anaemia (NG8)

This guideline covers diagnosing, assessing, managing and monitoring anaemia in people with chronic kidney disease. It aims to improve care for people with chronic kidney disease by specifying how to assess when their anaemia needs treating, and by making detailed recommendations on treatment with erythropoietic stimulating agents (ESAs) and iron. It also covers detecting and managing ESA-resistant anaemia.

NICE guideline Published June 2015

Chronic kidney disease in adults: assessment and management (CG182)

This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease.

Clinical guideline Published July 2014 Last updated January 2015

NICE impact: stroke

How NICE Recommendations are being used to improve care for people who are at risk of or who have had a stroke

Published May 2019 Last updated May 2019

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism

Technology appraisal guidance Published August 2015

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Technology appraisal guidance Published March 2015

AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fibrillation (MIB35)

Advice on the use of the AliveCor Heart Monitor and AliveECG (Kardia Mobile) app for detecting atrial fibrillation (AF) to aid local decision-making

Medtech innovation briefing Published August 2015

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block

Technology appraisal guidance Published November 2014

Research recommendations

TA245/1 | More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and

Published April 2016 Last updated April 2016

Thousands of strokes and deaths preventable from 'silent killer'

Thousands of strokes and deaths due to atrial fibrillation could be prevented each year by ensuring patients receive effective anticoagulant drugs, according to updated guidance from NICE.

News Published June 2014 Last updated June 2014

The NICE year in review – part 1

A quick look at the guidance and advice that has generated the most interest during the first half of the year.

News Published December 2014 Last updated December 2014

Offer anticoagulants instead of aspirin for stroke prevention

Adults with atrial fibrillation (AF) should be prescribed newer medications instead of aspirin for the prevention of stroke, says NICE.

News Published July 2015 Last updated July 2015

Novel oral anticoagulants an option for patients with atrial fibrillation

Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.

News Published June 2014 Last updated June 2014

New stroke prevention treatment recommended by NICE

Patients with atrial fibrilation can now be offered apixaban (Eliquis) as an alternative to warfarin to reduce the risk of stroke and blood clots, says NICE.

News Published February 2013 Last updated February 2013

Exploring the impact of NICE technology appraisals

As NICE publishes its 300th technology appraisal, we look back at the impact they have had on patient care.

News Published November 2013 Last updated November 2013

Improving production times for guidance on new pharmaceuticals

One of NICE?s regular functions is to produce recommendations on the use of new and existing medicines and treatments in the NHS.

News Published March 2013 Last updated March 2013